Publications 2025

Abrantes R, Forcados C, Warren DJ, Santos-Ferreira L, Fleten KG, Senra E, Costa AF, Krpina K, Henrique R, Liberg AM, Rawat P, Gelebart P, McCormack E, Bjørge L, Davidson B, Greiff V, Costea DE, Pinto F, Flatmark K, Gomes C, Inderberg EM, Reis CA, Wälchli S (2025)
Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors
6 (9), 102350
DOI 10.1016/j.xcrm.2025.102350, PubMed 40925376

Marhelava K, Fidyt K, Pepek M, Krawczyk M, Forcados C, Malinowska A, Swiderska B, Fernandez-Fuentes N, Czerwik N, Baranowska I, Krzywdzinska A, Sedek L, Slota L, Perkowski B, Villatoro A, Leray T, Lech-Maranda E, Menendez P, Inderberg EM, Wälchli S, Winiarska M, Firczuk M (2025)
LILRB1-directed CAR-T cells for the treatment of hematological malignancies
39 (6), 1395-1411
DOI 10.1038/s41375-025-02580-z, PubMed 40186066

Publications 2024

Bobrowicz M, Kusowska A, Krawczyk M, Zhylko A, Forcados C, Slusarczyk A, Barankiewicz J, Domagala J, Kubacz M, Šmída M, Dostalova L, Marhelava K, Fidyt K, Pepek M, Baranowska I, Szumera-Cieckiewicz A, Inderberg EM, Wälchli S, Granica M, Graczyk-Jarzynka A, Majchrzak M, Poreba M, Gehlert CL, Peipp M, Firczuk M et al. (2024)
CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies
13 (1), 2362454
DOI 10.1080/2162402X.2024.2362454, PubMed 38846084

Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, Benard E, Kaveh F, Caulier B, Helgestad Gjerde C, García de Jalón E, Warren DJ, Lindemann K, Rokkones E, Davidson B, Myhre MR, Kvalheim G, Bjørge L, McCormack E, Inderberg EM, Wälchli S (2024)
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16
12 (4)
DOI 10.1136/jitc-2023-008179, PubMed 38604812

Caulier B, Joaquina S, Gelebart P, Dowling TH, Kaveh F, Thomas M, Tandaric L, Wernhoff P, Katyayini NU, Wogsland C, Gjerstad ME, Fløisand Y, Kvalheim G, Marr C, Kobold S, Enserink JM, Gjertsen BT, McCormack E, Inderberg EM, Wälchli S (2024)
CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia
5 (6), 101572
DOI 10.1016/j.xcrm.2024.101572, PubMed 38754420

Maggadottir SM, Dueland S, Mensali N, Hamre H, Andresen PA, Myhre MR, Juul HV, Bigalke I, Lundby M, Hønnåshagen TK, Sæbøe-Larssen S, Josefsen D, Hagtvedt T, Wälchli S, Kvalheim G, Inderberg EM (2024)
Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer
32 (6), 2021-2029
DOI 10.1016/j.ymthe.2024.04.009, PubMed 38582964

Rosselle L, Leray T, Joaquina S, Caulier B, McCormack E, Gelebart P, Wälchli S, Inderberg EM (2024)
Protocol for production of tonic CAR T cells with dasatinib
6 (1), 103529
DOI 10.1016/j.xpro.2024.103529, PubMed 39739533

Safont MM, Leitch C, Popa M, Gjerstad ME, Caulier B, Inderberg EM, Wälchli S, Gelebart P, McCormack E (2024)
Protocol for the development of a bioluminescent AML-PDX mouse model for the evaluation of CAR T cell therapy
5 (4), 103522
DOI 10.1016/j.xpro.2024.103522, PubMed 39673705

Publications 2023

Casey NP, Klee CH, Fåne A, Caulier B, Graczyk-Jarzynka A, Krawczyk M, Fidyt K, Josefsson SE, Köksal H, Dillard P, Patkowska E, Firczuk M, Smeland EB, Winiarska M, Myklebust JH, Inderberg EM, Wälchli S (2023)
Efficient chimeric antigen receptor targeting of a central epitope of CD22
299 (7), 104883
DOI 10.1016/j.jbc.2023.104883, PubMed 37269947

Joaquina S, Forcados C, Caulier B, Inderberg EM, Wälchli S (2023)
Determination of CAR T cell metabolism in an optimized protocol
11, 1207576
DOI 10.3389/fbioe.2023.1207576, PubMed 37409169

Klee CH, Villatoro A, Casey NP, Inderberg EM, Wälchli S (2023)
In vitro re-challenge of CAR T cells
183, 335-353
DOI 10.1016/bs.mcb.2023.06.003, PubMed 38548418

Mensali N, Köksal H, Joaquina S, Wernhoff P, Casey NP, Romecin P, Panisello C, Rodriguez R, Vimeux L, Juzeniene A, Myhre MR, Fåne A, Ramírez CC, Maggadottir SM, Duru AD, Georgoudaki AM, Grad I, Maturana AD, Gaudernack G, Kvalheim G, Carcaboso AM, de Alava E, Donnadieu E, Bruland ØS, Menendez P et al. (2023)
ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma
14 (1), 3375
DOI 10.1038/s41467-023-39097-x, PubMed 37291203

Publications 2022

Abrantes R, Duarte HO, Gomes C, Wälchli S, Reis CA (2022)
CAR-Ts: new perspectives in cancer therapy
596 (4), 403-416
DOI 10.1002/1873-3468.14270, PubMed 34978080

Bajor M, Graczyk-Jarzynka A, Marhelava K, Burdzinska A, Muchowicz A, Goral A, Zhylko A, Soroczynska K, Retecki K, Krawczyk M, Klopotowska M, Pilch Z, Paczek L, Malmberg KJ, Wälchli S, Winiarska M, Zagozdzon R (2022)
PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
10 (1)
DOI 10.1136/jitc-2021-002500, PubMed 35078921

Forcados C, Joaquina S, Casey NP, Caulier B, Wälchli S (2022)
How CAR T Cells Breathe
11 (9)
DOI 10.3390/cells11091454, PubMed 35563759

Huse K, Bai B, Hilden VI, Bollum LK, Våtsveen TK, Munthe LA, Smeland EB, Irish JM, Wälchli S, Myklebust JH (2022)
Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression
209 (10), 2042-2053
DOI 10.4049/jimmunol.2200144, PubMed 36426942

Maggadóttir SM, Kvalheim G, Wernhoff P, Sæbøe-Larssen S, Revheim ME, Josefsen D, Wälchli S, Helland Å, Inderberg EM (2022)
A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
12, 1031232
DOI 10.3389/fonc.2022.1031232, PubMed 36439452

Publications 2021

Caulier B, Enserink JM, Wälchli S (2021)
Pharmacologic Control of CAR T Cells
22 (9)
DOI 10.3390/ijms22094320, PubMed 33919245

Dillard P, Casey N, Pollmann S, Vernhoff P, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2021)
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
10 (1), 1936757
DOI 10.1080/2162402X.2021.1936757, PubMed 34235003

Fåne A, Myhre MR, Inderberg EM, Wälchli S (2021)
In vivo experimental mouse model to test CD19CAR T cells generated with different methods
167, 149-161
DOI 10.1016/bs.mcb.2021.11.001, PubMed 35152992

Ito J, Minemura T, Wälchli S, Niimi T, Fujihara Y, Kuroda S, Takimoto K, Maturana AD (2021)
Id2 Represses Aldosterone-Stimulated Cardiac T-Type Calcium Channels Expression
22 (7)
DOI 10.3390/ijms22073561, PubMed 33808082

Mensali N, Dillard P, Fayzullin A, Köksal H, Gaudernack G, Kvalheim G, Inderberg EM, Wälchli S (2021)
"Built-in" PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms
35 (9), e21750
DOI 10.1096/fj.202100025R, PubMed 34424568

Vestre K, Persiconi I, Borg Distefano M, Mensali N, Guadagno NA, Bretou M, Wälchli S, Arnold-Schrauf C, Bakke O, Dalod M, Lennon-Dumenil AM, Progida C (2021)
Rab7b regulates dendritic cell migration by linking lysosomes to the actomyosin cytoskeleton
134 (18)
DOI 10.1242/jcs.259221, PubMed 34494097

Publications 2020

Bai B, Myklebust JH, Wälchli S (2020)
Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology
2115, 445-454
DOI 10.1007/978-1-0716-0290-4_25, PubMed 32006416

Benard E, Casey NP, Inderberg EM, Wälchli S (2020)
SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy
92 (4), e12917
DOI 10.1111/sji.12917, PubMed 32557659

Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2020)
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
29 (3), 1199-1213
DOI 10.1016/j.ymthe.2020.11.019, PubMed 33212301

Dillard P, Lie M, Baken E, Lobert VH, Benard E, Köksal H, Inderberg EM, Wälchli S (2020)
Colorectal cysts as a validating tool for CAR therapy
20 (1), 30
DOI 10.1186/s12896-020-00623-0, PubMed 32487146

Inderberg EM, Wälchli S (2020)
Long-term surviving cancer patients as a source of therapeutic TCR
69 (5), 859-865
DOI 10.1007/s00262-019-02468-9, PubMed 31915853

Inderberg EM, Wälchli S (2020)
Sympathetic improvement of cancer vaccine efficacy
16 (8), 1888-1890
DOI 10.1080/21645515.2019.1703456, PubMed 31977269

Köksal H, Dillard P, Juzeniene A, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2020)
Combinatorial CAR design improves target restriction
296, 100116
DOI 10.1074/jbc.RA120.016234, PubMed 33234592

Mensali N, Myhre MR, Dillard P, Pollmann S, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2020)
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
69 (1), 159-161
DOI 10.1007/s00262-019-02409-6, PubMed 31776597

Winge-Main AK, Wälchli S, Inderberg EM (2020)
T cell receptor therapy against melanoma-Immunotherapy for the future?
92 (4), e12927
DOI 10.1111/sji.12927, PubMed 32640053

Wälchli S, Sioud M (2020)
Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted?
2115, 407-417
DOI 10.1007/978-1-0716-0290-4_22, PubMed 32006413

Publications 2019

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH (2019)
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
7 (3), 355-362
DOI 10.1158/2326-6066.CIR-18-0351, PubMed 30659053

Köksal H, Baken E, Warren DJ, Løset GÅ, Inderberg EM, Wälchli S (2019)
Chimeric antigen receptor preparation from hybridoma to T-cell expression
2 (2), 56-63
DOI 10.1093/abt/tbz007, PubMed 33928223

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2019)
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
3 (8), 1230-1243
DOI 10.1182/bloodadvances.2018029678, PubMed 30979721

Köksal H, Müller E, Inderberg EM, Bruland Ø, Wälchli S (2019)
Treating osteosarcoma with CAR T cells
89 (3), e12741
DOI 10.1111/sji.12741, PubMed 30549299

Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Wälchli S (2019)
NK cells specifically TCR-dressed to kill cancer cells
40, 106-117
DOI 10.1016/j.ebiom.2019.01.031, PubMed 30665853

Mensali N, Grenov A, Pati NB, Dillard P, Myhre MR, Gaudernack G, Kvalheim G, Inderberg EM, Bakke O, Wälchli S (2019)
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
8 (3), 1558663
DOI 10.1080/2162402X.2018.1558663, PubMed 30723591

Mensali N, Myhre MR, Dillard P, Pollmann S, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2019)
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
68 (8), 1235-1243
DOI 10.1007/s00262-019-02356-2, PubMed 31214732

Theodossiou TA, Ali M, Grigalavicius M, Grallert B, Dillard P, Schink KO, Olsen CE, Wälchli S, Inderberg EM, Kubin A, Peng Q, Berg K (2019)
Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy
5, 13
DOI 10.1038/s41523-019-0108-8, PubMed 30993194

Publications 2018

Dillard P, Köksal H, Inderberg EM, Wälchli S (2018)
A Spheroid Killing Assay by CAR T Cells
(142)
DOI 10.3791/58785, PubMed 30596389

Lampen MH, Uchtenhagen H, Blom K, Varnaitė R, Pakalniene J, Dailidyte L, Wälchli S, Lindquist L, Mickiene A, Michaëlsson J, Schumacher TN, Ljunggren HG, Sandberg JK, Achour A, Gredmark-Russ S (2018)
Breadth and Dynamics of HLA-A2- and HLA-B7-Restricted CD8⁺ T Cell Responses against Nonstructural Viral Proteins in Acute Human Tick-Borne Encephalitis Virus Infection
2 (6), 172-184
DOI 10.4049/immunohorizons.1800029, PubMed 31022685

Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP (2018)
Artesunate shows potent anti-tumor activity in B-cell lymphoma
11 (1), 23
DOI 10.1186/s13045-018-0561-0, PubMed 29458389

Publications 2017

Bollum LK, Huse K, Oksvold MP, Bai B, Hilden VI, Forfang L, Yoon SO, Wälchli S, Smeland EB, Myklebust JH (2017)
BMP-7 induces apoptosis in human germinal center B cells and is influenced by TGF-β receptor type I ALK5
12 (5), e0177188
DOI 10.1371/journal.pone.0177188, PubMed 28489883

Inderberg EM, Mensali N, Oksvold MP, Fallang LE, Fåne A, Skorstad G, Stenvik GE, Progida C, Bakke O, Kvalheim G, Myklebust JH, Wälchli S (2017)
Human c-SRC kinase (CSK) overexpression makes T cells dummy
67 (4), 525-536
DOI 10.1007/s00262-017-2105-9, PubMed 29248956

Inderberg EM, Wälchli S, Myhre MR, Trachsel S, Almåsbak H, Kvalheim G, Gaudernack G (2017)
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
6 (4), e1302631
DOI 10.1080/2162402X.2017.1302631, PubMed 28507809

Koksal H, Walchli S (2017)
Fishing therapeutic T-cell receptors in healthy donor blood, is safety predictable?
Transl. Cancer Res., 6 3, S622-S624
DOI 10.21037/tcr.2017.05.25

Walseng E, Köksal H, Sektioglu IM, Fåne A, Skorstad G, Kvalheim G, Gaudernack G, Inderberg EM, Wälchli S (2017)
A TCR-based Chimeric Antigen Receptor
7 (1), 10713
DOI 10.1038/s41598-017-11126-y, PubMed 28878363

Publications 2016

Belnoue E, Di Berardino-Besson W, Gaertner H, Carboni S, Dunand-Sauthier I, Cerini F, Suso-Inderberg EM, Wälchli S, König S, Salazar AM, Hartley O, Dietrich PY, Walker PR, Derouazi M (2016)
Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants
24 (9), 1675-85
DOI 10.1038/mt.2016.134, PubMed 27377043

Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
5 (12), e1249090
DOI 10.1080/2162402X.2016.1249090, PubMed 28123886

Mensali N, Ying F, Sheng VO, Yang W, Walseng E, Kumari S, Fallang LE, Kolstad A, Uckert W, Malmberg KJ, Wälchli S, Olweus J (2016)
Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA
5 (5), e1138199
DOI 10.1080/2162402X.2016.1138199, PubMed 27467957

Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R (2016)
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling
129 (6), 759-770
DOI 10.1182/blood-2016-05-718494, PubMed 28011673

Publications 2015

Tadesse FG, Mensali N, Fallang LE, Walseng E, Yang W, Olweus J, Wälchli S (2015)
Unpredicted phenotypes of two mutants of the TcR DMF5
425, 37-44
DOI 10.1016/j.jim.2015.06.006, PubMed 26079729

Theodossiou TA, Wälchli S, Olsen CE, Skarpen E, Berg K (2015)
Deciphering the Nongenomic, Mitochondrial Toxicity of Tamoxifens As Determined by Cell Metabolism and Redox Activity
11 (1), 251-62
DOI 10.1021/acschembio.5b00734, PubMed 26569462

Walseng E, Wälchli S, Fallang LE, Yang W, Vefferstad A, Areffard A, Olweus J (2015)
Soluble T-cell receptors produced in human cells for targeted delivery
10 (4), e0119559
DOI 10.1371/journal.pone.0119559, PubMed 25875651

Publications 2013

Gregers TF, Skånland SS, Wälchli S, Bakke O, Sandvig K (2013)
BiP negatively affects ricin transport
5 (5), 969-82
DOI 10.3390/toxins5050969, PubMed 23666197

Kumari S, Wälchli S, Fallang LE, Yang W, Lund-Johansen F, Schumacher TN, Olweus J (2013)
Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes
111 (1), 403-8
DOI 10.1073/pnas.1306549111, PubMed 24344295

Wälchli S, Kumari S, Fallang LE, Sand KM, Yang W, Landsverk OJ, Bakke O, Olweus J, Gregers TF (2013)
Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation
44 (3), 774-84
DOI 10.1002/eji.201343671, PubMed 24293164

Publications 2012

Huse K, Bakkebø M, Wälchli S, Oksvold MP, Hilden VI, Forfang L, Bredahl ML, Liestøl K, Alizadeh AA, Smeland EB, Myklebust JH (2012)
Role of Smad proteins in resistance to BMP-induced growth inhibition in B-cell lymphoma
7 (10), e46117
DOI 10.1371/journal.pone.0046117, PubMed 23049692

Zhen Y, Sørensen V, Skjerpen CS, Haugsten EM, Jin Y, Wälchli S, Olsnes S, Wiedlocha A (2012)
Nuclear import of exogenous FGF1 requires the ER-protein LRRC59 and the importins Kpnα1 and Kpnβ1
13 (5), 650-64
DOI 10.1111/j.1600-0854.2012.01341.x, PubMed 22321063

Publications 2011

Abrahamsen IW, Kjellevoll S, Greve-Isdahl M, Mensali N, Wälchli S, Kumari S, Loland BF, Egeland T, Kolstad A, Olweus J (2011)
T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells
130 (8), 1821-32
DOI 10.1002/ijc.26209, PubMed 21630262

Sokołowska I, Wälchli S, Węgrzyn G, Sandvig K, Słomińska-Wojewódzka M (2011)
A single point mutation in ricin A-chain increases toxin degradation and inhibits EDEM1-dependent ER retrotranslocation
436 (2), 371-85
DOI 10.1042/BJ20101493, PubMed 21388347

Wälchli S, Løset GÅ, Kumari S, Johansen JN, Yang W, Sandlie I, Olweus J (2011)
A practical approach to T-cell receptor cloning and expression
6 (11), e27930
DOI 10.1371/journal.pone.0027930, PubMed 22132171

Publications 2010

Abrahamsen IW, Stronen E, Wälchli S, Johansen JN, Kjellevoll S, Kumari S, Komada M, Gaudernack G, Tjonnfjord G, Toebes M, Schumacher TN, Lund-Johansen F, Olweus J (2010)
Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif
24 (11), 1901-9
DOI 10.1038/leu.2010.186, PubMed 20844564

Almåsbak H, Rian E, Hoel HJ, Pulè M, Wälchli S, Kvalheim G, Gaudernack G, Rasmussen AM (2010)
Transiently redirected T cells for adoptive transfer
13 (5), 629-40
DOI 10.3109/14653249.2010.542461, PubMed 21174490

Yamazaki T, Wälchli S, Fujita T, Ryser S, Hoshijima M, Schlegel W, Kuroda S, Maturana AD (2010)
Splice variants of enigma homolog, differentially expressed during heart development, promote or prevent hypertrophy
86 (3), 374-82
DOI 10.1093/cvr/cvq023, PubMed 20097676

Publications 2009

Raa H, Grimmer S, Schwudke D, Bergan J, Wälchli S, Skotland T, Shevchenko A, Sandvig K (2009)
Glycosphingolipid requirements for endosome-to-Golgi transport of Shiga toxin
10 (7), 868-82
DOI 10.1111/j.1600-0854.2009.00919.x, PubMed 19453975

Skånland SS, Wälchli S, Brech A, Sandvig K (2009)
SNX4 in complex with clathrin and dynein: implications for endosome movement
4 (6), e5935
DOI 10.1371/journal.pone.0005935, PubMed 19529763

Skånland SS, Wälchli S, Sandvig K (2009)
β-arrestins attenuate p38-mediated endosome to Golgi transport
11 (5), 796-807
DOI 10.1111/j.1462-5822.2009.01292.x, PubMed 19159388

Stronen E, Abrahamsen IW, Gaudernack G, Wälchli S, Munthe E, Buus S, Johansen FE, Lund-Johansen F, Olweus J (2009)
Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells
69 (4), 319-28
DOI 10.1111/j.1365-3083.2008.02223.x, PubMed 19284496

Wälchli S, Aasheim HC, Skånland SS, Spilsberg B, Torgersen ML, Rosendal KR, Sandvig K (2009)
Characterization of clathrin and Syk interaction upon Shiga toxin binding
21 (7), 1161-8
DOI 10.1016/j.cellsig.2009.03.005, PubMed 19289168

Publications 2008

Maturana AD, Wälchli S, Iwata M, Ryser S, Van Lint J, Hoshijima M, Schlegel W, Ikeda Y, Tanizawa K, Kuroda S (2008)
Enigma homolog 1 scaffolds protein kinase D1 to regulate the activity of the cardiac L-type voltage-gated calcium channel
78 (3), 458-65
DOI 10.1093/cvr/cvn052, PubMed 18296710

Nygren MK, Døsen-Dahl G, Stubberud H, Wälchli S, Munthe E, Rian E (2008)
beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells
37 (2), 225-33
DOI 10.1016/j.exphem.2008.10.007, PubMed 19101069

Sørensen V, Zhen Y, Zakrzewska M, Haugsten EM, Wälchli S, Nilsen T, Olsnes S, Wiedlocha A (2008)
Phosphorylation of fibroblast growth factor (FGF) receptor 1 at Ser777 by p38 mitogen-activated protein kinase regulates translocation of exogenous FGF1 to the cytosol and nucleus
28 (12), 4129-41
DOI 10.1128/MCB.02117-07, PubMed 18411303

Walchli S, Sioud M (2008)
Vector-based delivery of siRNAs: in vitro and in vivo challenges
13, 3488-93
DOI 10.2741/2943, PubMed 18508450

Walchli S, Sioud M (2008)
Vector-based delivery of siRNAs: In vitro and in vivo challenges
Front. Biosci., 13, 3488-3493

Publications 2007

Fujita T, Maturana AD, Ikuta J, Hamada J, Walchli S, Suzuki T, Sawa H, Wooten MW, Okajima T, Tatematsu K, Tanizawa K, Kuroda S (2007)
Axonal guidance protein FEZ1 associates with tubulin and kinesin motor protein to transport mitochondria in neurites of NGF-stimulated PC12 cells
361 (3), 605-10
DOI 10.1016/j.bbrc.2007.07.050, PubMed 17669366

Skånland SS, Wälchli S, Utskarpen A, Wandinger-Ness A, Sandvig K (2007)
Phosphoinositide-regulated retrograde transport of ricin: crosstalk between hVps34 and sorting nexins
8 (3), 297-309
DOI 10.1111/j.1600-0854.2006.00527.x, PubMed 17319803

Torgersen ML, Wälchli S, Grimmer S, Skånland SS, Sandvig K (2007)
Protein kinase Cdelta is activated by Shiga toxin and regulates its transport
282 (22), 16317-28
DOI 10.1074/jbc.M610886200, PubMed 17403690

Wälchli S, Skånland SS, Gregers TF, Lauvrak SU, Torgersen ML, Ying M, Kuroda S, Maturana A, Sandvig K (2007)
The Mitogen-activated protein kinase p38 links Shiga Toxin-dependent signaling and trafficking
19 (1), 95-104
DOI 10.1091/mbc.e07-06-0565, PubMed 17959827

Publications 2006

Bache KG, Stuffers S, Malerød L, Slagsvold T, Raiborg C, Lechardeur D, Wälchli S, Lukacs GL, Brech A, Stenmark H (2006)
The ESCRT-III subunit hVps24 is required for degradation but not silencing of the epidermal growth factor receptor
17 (6), 2513-23
DOI 10.1091/mbc.e05-10-0915, PubMed 16554368

Huynh T, Wälchli S, Sioud M (2006)
Transcriptional targeting of small interfering RNAs into cancer cells
350 (4), 854-9
DOI 10.1016/j.bbrc.2006.09.127, PubMed 17034763

Slominska-Wojewodzka M, Gregers TF, Wälchli S, Sandvig K (2006)
EDEM is involved in retrotranslocation of ricin from the endoplasmic reticulum to the cytosol
17 (4), 1664-75
DOI 10.1091/mbc.e05-10-0961, PubMed 16452630

Utskarpen A, Slagsvold HH, Iversen TG, Wälchli S, Sandvig K (2006)
Transport of ricin from endosomes to the Golgi apparatus is regulated by Rab6A and Rab6A'
7 (6), 663-72
DOI 10.1111/j.1600-0854.2006.00418.x, PubMed 16683916

Publications 2005

Grimmer S, Ying M, Wälchli S, van Deurs B, Sandvig K (2005)
Golgi vesiculation induced by cholesterol occurs by a dynamin- and cPLA2-dependent mechanism
6 (2), 144-56
DOI 10.1111/j.1600-0854.2005.00258.x, PubMed 15634214

Hetz C, Russelakis-Carneiro M, Wälchli S, Carboni S, Vial-Knecht E, Maundrell K, Castilla J, Soto C (2005)
The disulfide isomerase Grp58 is a protective factor against prion neurotoxicity
25 (11), 2793-802
DOI 10.1523/JNEUROSCI.4090-04.2005, PubMed 15772339

Lauvrak SU, Wälchli S, Iversen TG, Slagsvold HH, Torgersen ML, Spilsberg B, Sandvig K (2005)
Shiga toxin regulates its entry in a Syk-dependent manner
17 (3), 1096-109
DOI 10.1091/mbc.e05-08-0766, PubMed 16371508

Sioud M, Wälchli S (2005)
Strategies for the design of random siRNA libraries and the selection of anti-GFP siRNAs
309, 83-91
DOI 10.1385/1-59259-935-4:083, PubMed 15990399

Spilsberg B, Sandvig K, Wälchli S (2005)
Reconstitution of active diphtheria toxin based on a hexahistidine tagged version of the B-fragment produced to high yields in bacteria
46 (8), 900-6
DOI 10.1016/j.toxicon.2005.08.015, PubMed 16260019

Wälchli S, Espanel X, Hooft van Huijsduijnen R (2005)
Sap-1/PTPRH activity is regulated by reversible dimerization
331 (2), 497-502
DOI 10.1016/j.bbrc.2005.03.196, PubMed 15850787

Publications 2003

Espanel X, Wälchli S, Rückle T, Harrenga A, Huguenin-Reggiani M, Hooft van Huijsduijnen R (2003)
Mapping of synergistic components of weakly interacting protein-protein motifs using arrays of paired peptides
278 (17), 15162-7
DOI 10.1074/jbc.M211887200, PubMed 12551909

Pasquali C, Curchod ML, Wälchli S, Espanel X, Guerrier M, Arigoni F, Strous G, Hooft van Huijsduijnen R (2003)
Identification of protein tyrosine phosphatases with specificity for the ligand-activated growth hormone receptor
17 (11), 2228-39
DOI 10.1210/me.2003-0011, PubMed 12907755

Sozio MS, Mathis MA, Young JA, Wälchli S, Pitcher LA, Wrage PC, Bartók B, Campbell A, Watts JD, Aebersold R, Hooft van Huijsduijnen R, van Oers NS (2003)
PTPH1 is a predominant protein-tyrosine phosphatase capable of interacting with and dephosphorylating the T cell receptor zeta subunit
279 (9), 7760-9
DOI 10.1074/jbc.M309994200, PubMed 14672952

Wälchli S, Espanel X, Harrenga A, Rossi M, Cesareni G, Hooft van Huijsduijnen R (2003)
Probing protein-tyrosine phosphatase substrate specificity using a phosphotyrosine-containing phage library
279 (1), 311-8
DOI 10.1074/jbc.M307617200, PubMed 14578355

Publications 2002

Hooft van Huijsduijnen R, Wälchli S, Ibberson M, Harrenga A (2002)
Protein tyrosine phosphatases as drug targets: PTP1B and beyond
6 (6), 637-47
DOI 10.1517/14728222.6.6.637, PubMed 12472377

Publications 2001

Espanel X, Wälchli S, Gobert RP, El Alama M, Curchod ML, Gullu-Isler N, Hooft van Huijsduijnen R (2001)
Pulling strings below the surface: hormone receptor signaling through inhibition of protein tyrosine phosphatases
15 (1), 19-28
DOI 10.1385/endo:15:1:019, PubMed 11572321

Publications 2000

Wälchli S, Colinge J, Hooft van Huijsduijnen R (2000)
MetaBlasts: tracing protein tyrosine phosphatase gene family roots from Man to Drosophila melanogaster and Caenorhabditis elegans genomes
253 (2), 137-43
DOI 10.1016/s0378-1119(00)00275-4, PubMed 10940550

Wälchli S, Curchod ML, Gobert RP, Arkinstall S, Hooft van Huijsduijnen R (2000)
Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A brute force approach based on "substrate-trapping" mutants
275 (13), 9792-6
DOI 10.1074/jbc.275.13.9792, PubMed 10734133